Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Mojun Zhu, Mohamad Bassam Sonbol, Thorvardur Halfdanarson, Timothy Hobday, Daniel Ahn, Wen Wee Ma, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

Abstract

Lutetium-177-dotatate (177Lu-dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of the NETTER-1 trial for grade 1–2 midgut NETs. Here, we present a patient with a grade 3 pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to 177Lu-dotatate.

Original languageEnglish (US)
Pages (from-to)e1246-e1248
JournalOncologist
Volume25
Issue number8
DOIs
StatePublished - Aug 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors'. Together they form a unique fingerprint.

Cite this